Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/4/2024 | $3.50 → $3.00 | Overweight → Equal Weight | Barclays |
3/1/2024 | Overweight → Neutral | JP Morgan | |
12/8/2023 | Underweight → Equal-Weight | Morgan Stanley | |
12/7/2023 | Buy | Citigroup | |
11/22/2023 | Hold | Jefferies | |
7/10/2023 | Neutral → Buy | BofA Securities | |
5/24/2023 | $3.74 | Outperform | Bernstein |
1/12/2023 | Sell → Buy | UBS |
6-K - AMBEV S.A. (0001565025) (Filer)
6-K - AMBEV S.A. (0001565025) (Filer)
6-K - AMBEV S.A. (0001565025) (Filer)
SÃO PAULO, March 11, 2024 /PRNewswire/ -- Ambev S.A. ([B3: ABEV3, NYSE:ABEV) announces that the Company's annual report on Form 20-F for the year ended December 31, 2023 was filed with the U.S. Securities and Exchange Commission - SEC ("SEC") on March 11, 2024 and is available on the Company's website (ri.ambev.com.br) and also on the SEC (www.sec.gov/edgar/). ADR holders may receive a hard copy of the Company's complete audited financial statements contained in the Form 20-F free of charge, upon request. To access the full document, please access the following links: click here. Ambev S.A. Investor Relations DepartmentContact e-mail: [email protected] View original content:https://www
SÃO PAULO, March 17, 2023 /PRNewswire/ -- Ambev S.A. ([B3: ABEV3, NYSE:ABEV) announces that the Company's annual report on Form 20-F for the year ended December 31, 2022 was filed with the U.S. Securities and Exchange Commission - SEC (www.sec.gov) on March 17, 2023 and is available on the Company's website (ri.ambev.com.br) and also on the Company's page on SEC's database (www.sec.gov/edgar/). ADR holders may receive a hard copy of the Company's complete audited financial statements contained in the Form 20-F free of charge, upon request. To access the full document, please access the following links: click here. CONTACT: Ambev S.A.Investor Relations DepartmentContact e-mail: [email protected]
SÃO PAULO, Brazil, March 18, 2022 (GLOBE NEWSWIRE) -- Ambev S.A. ([B3: ABEV3, NYSE:ABEV) announces that the Company's annual report on Form 20-F for the year ended December 31, 2021 was filed with the U.S. Securities and Exchange Commission - SEC (www.sec.gov) on March 18, 2022 and is available on the Company's website (ri.ambev.com.br) and also on the Company's page on SEC's database (www.sec.gov/edgar/). ADR holders may receive a hard copy of the Company's complete audited financial statements contained in the Form 20-F free of charge, upon request. To access the full document, please access the following link: click here Ambev S.A. Investor Relations Department Contact e-mail: ri@amb
Barclays analyst Benjamin Theurer maintains Ambev (NYSE:ABEV) with a Equal-Weight and lowers the price target from $3 to $2.5.
Brazilian brewing company Ambev SA (NYSE:ABEV) reported first-quarter FY24 net revenue decline of 1.2% to R$20.3 billion. On an organic basis, net revenue gained 4.5%. Net revenue per hl slipped 1.4%. Consolidated volume was virtually flat (+0.1%), as positive performances in Brazil (+6.5% in NAB and +3.6% in Beer) and Central America and the Caribbean (CAC) (+5.6%) were offset by Latin America South (-12.7%) and Canada (-7.7%). Gross profit for the quarter dropped 1.8% to R$10.2 billion, and the margin contracted 30 basis points to 50.4%. Normalized profit dropped 0.6% to R$3.8 billion. Normalized EBITDA climbed 1.4% to R$6.5 billion, and the normalized EBITDA margin expanded by 80
Barclays downgraded AmBev from Overweight to Equal Weight and set a new price target of $3.00 from $3.50 previously
JP Morgan downgraded AmBev from Overweight to Neutral
Morgan Stanley upgraded AmBev from Underweight to Equal-Weight